(-0.25%) 5 023.05 points
(0.30%) 37 931 points
(-0.30%) 15 610 points
(-3.14%) $79.36
(-2.51%) $1.941
(0.50%) $2 314.40
(0.32%) $26.74
(1.19%) $959.45
(-0.01%) $0.937
(-0.05%) $11.09
(0.13%) $0.801
(-0.48%) $93.00
0.00% ¥ 744.00
Live Chart Being Loaded With Signals
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL...
Stats | |
---|---|
Volumen de hoy | 40 000.00 |
Volumen promedio | 76 857.00 |
Capitalización de mercado | 40.59B |
EPS | ¥0 ( 2024-02-14 ) |
Próxima fecha de ganancias | ( ¥0 ) 2024-05-10 |
Last Dividend | ¥13.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 30.31 |
ATR14 | ¥0.382 (0.05%) |
Seikagaku Corporation Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Seikagaku Corporation Correlación - Moneda/Commodity
Seikagaku Corporation Finanzas
Annual | 2022 |
Ingresos: | ¥33.46B |
Beneficio Bruto: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
Ingresos: | ¥33.46B |
Beneficio Bruto: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
Ingresos: | ¥34.85B |
Beneficio Bruto: | ¥20.53B (58.90 %) |
EPS: | ¥66.32 |
FY | 2021 |
Ingresos: | ¥27.66B |
Beneficio Bruto: | ¥15.55B (56.21 %) |
EPS: | ¥75.54 |
Financial Reports:
No articles found.
Seikagaku Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥13.00 (N/A) |
¥0 (N/A) |
¥13.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.44 | 2004-03-26 |
Last Dividend | ¥13.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | ¥437.61 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.38 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.53 | |
Div. Directional Score | 6.61 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9531.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8174.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7552.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6101.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4812.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4026.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
3242.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
2267.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9042.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0377 | 1.500 | 9.25 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0164 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0187 | 1.500 | -0.903 | -1.355 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.08 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.79 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00493 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 258.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00549 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.505 | 1.000 | 4.91 | 4.91 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0298 | 1.000 | -1.403 | -1.403 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.434 | 0.800 | -0.439 | -0.351 | [0.5 - 2] |
Total Score | 10.68 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 30.97 | 1.000 | 6.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0187 | 2.50 | -0.581 | -1.355 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.50 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.54 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0914 | 1.000 | -0.216 | 0 | [0.1 - 0.5] |
Total Score | 2.53 |
Seikagaku Corporation
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico